NEW
YORK, May 22, 2024 /PRNewswire/ -- Perseus
Therapeutics, a pioneering biopharmaceutical company based in
New York City, is proud to
announce the development of a novel thymic stromal lymphopoietin
(TSLP) antibody aimed at preventing hair loss in cancer patients
and treating a range of inflammatory diseases, including
asthma.
TSLP antibodies have recently gained significant attention in
the medical and pharmaceutical communities. These antibodies have
shown potential in addressing various inflammatory and allergic
conditions, driven by their promising efficacy data and the unmet
medical needs they aim to fulfill.
Several companies and research groups are actively exploring
TSLP antibodies, with notable developments including:
- AstraZeneca and Amgen have developed Tezepelumab, the
first-in-class anti-TSLP monoclonal antibody approved for severe
asthma treatment.
- Johnson & Johnson acquired Proteologix to access its
bispecific antibody targeting TSLP and IL-13.
- Blackstone has launched Uniquity to advance Merck's
Phase 2 high potency TSLP antibody.
- Innovent Biologics is conducting a Phase I study on
IBI3002, a dual-function antibody targeting both IL-4Rα and
TSLP.
- Sanofi and Regeneron are developing SAR443765, a novel biologic targeting both TSLP
and IL-13 for asthma.
- Teva Pharmaceuticals and Biolojic Design have
entered into an exclusive license agreement to develop bispecific
antibodies targeting TSLP and IL-13.
- GSK recently acquired Aiolos Bio for $1 billion upfront to enhance its respiratory
biologics portfolio with AIO-001, a Phase 2 long-acting anti-TSLP
monoclonal antibody.
These strategic moves underscore the growing interest in TSLP
antibodies for treating a wide range of inflammatory and allergic
conditions. Perseus Therapeutics is poised to contribute to this
dynamic field with its innovative approach to preventing hair loss
in cancer patients, a common and distressing side effect of cancer
treatments, and addressing other inflammatory diseases.
"Perseus Therapeutics is committed to advancing the science of
TSLP antibodies to meet critical unmet medical needs," said
Joseph Hernandez, Chairman and
Founder of Perseus Therapeutics. "Our work aims not only to improve
the quality of life for cancer patients by preventing hair loss but
also to provide effective treatments for various inflammatory
conditions."
For more information about Perseus Therapeutics and its pipeline
of innovative therapies, please visit www.perseustherapeutics.com
or contact media@perseustherapeutics.com.
About Perseus Therapeutics, Inc.
Perseus Therapeutics
is a Duke University spinout
biopharmaceutical company dedicated to developing innovative
therapies for cancer patients and those suffering from inflammatory
diseases. Based in New York City,
Perseus Therapeutics is at the forefront of antibody research and
development, striving to bring new hope and improved outcomes to
patients worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perseus-therapeutics-announces-development-of-tslp-antibody-for-prevention-of-hair-loss-in-cancer-patients-and-treatment-of-inflammatory-diseases-with-well-known-cro-partner-302153182.html
SOURCE Perseus Therapeutics, Inc.